Humira Under Pressure As NHS England Invites 'Competitive Prices' For Biosimilars
Executive Summary
Companies wanting to compete in the newly off-patent adalimumab market in England have until Oct. 22 to submit their bids. They will need to offer “competitive prices” if they are to secure the highest share of sales to the national health service. At the same time, NHS trusts and clinical commissioning groups have been warned not to accept discounted interim offers from suppliers keen to get a foot in the door.
You may also be interested in...
Boehringer Bails On Biosimilars Outside US
In a strategic shift confirmed by the German company, BI's Humira biosimilar Cyltezo will only be launched in the US while its version of Avastin has been abandoned altogether.
Boehringer Bails On Biosimilars Outside US
In a strategic shift confirmed by the German company, BI's Humira biosimilar Cyltezo will only be launched in the US while its version of Avastin has been abandoned altogether.
UK Must Use Biosimilar Savings To Provide Earlier Access To Biologics
The UK may be busy sweeping up the savings being generated with the rapid uptake of biosimilars, but more needs to be done to show how this money is being channelled back into the healthcare system to the benefit of patients.